AGIO | tickerfilter.com

Fundamental analysis

43%

Profitability 35%

Dept financing 20%

Liquidity 75%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.46%

1 Month

6.10%

3 Months

1.66%

6 Months

-21.72%

1 Year

-16.97%

2 Year

-10.14%

Key data

Stock price

$28.19

P/E Ratio

0.00

DAY RANGE

$28.13 - $29.37

EPS

-$7.12

52 WEEK RANGE

$22.24 - $46.00

52 WEEK CHANGE

-$17.04

MARKET CAP

1.587 B

YIELD

N/A

SHARES OUTSTANDING

58.592 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-31-2025

BETA

1.74

PUBLIC FLOAT

AVERAGE 10 VOLUME

$917,220

AVERAGE 30 VOLUME

$879,386

Company detail

CEO: Brian M. Goff
Region: US
Website: agios.com
Employees: 390
IPO year: 2013

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Agios Pharmaceuticals, Inc. engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes. AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.

AGIO - AGIOS PHARMACEUTICALS, INC.